Hangzhou Sumgen Biotech Co., Ltd.

This study tests an experimental drug called SG1906 in people with advanced solid tumors that have a specific protein (CLDN18.2) on their surface. The trial has two parts: first, finding the safest dose, and then checking for early signs that the drug can shrink tumors. About 60 …

This Phase 2 trial tests an experimental drug called SG301, given as a weekly injection, for adults with primary immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising bleeding risk. The study includes about 60 people who have not improved…

This study tests an experimental drug called SG2918 in 40 people with relapsed or refractory multiple myeloma, a type of blood cancer that has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and how well the body tolerates it, wi…

This phase 3 trial tests whether adding an experimental drug called SG301 to two standard medications (pomalidomide and dexamethasone) can help people with multiple myeloma that has come back or stopped responding to treatment. About 360 adults aged 18–75 with measurable disease …

This phase 2 trial tests a new drug called SG301, given as a shot under the skin, for people with systemic lupus erythematosus (SLE). About 120 participants whose lupus is not well controlled by standard treatments will receive either SG301 or a placebo over several months. The g…